KRAS-G12V mRNA Vaccine and Pembrolizumab in Advanced Solid Tumors: Case report
Description
Here, we report two patients of advanced solid tumor both of whom achieved partial response after treated with combination therapy using an mRNA vaccine targeting KRAS G12V mutation and Pembrolizumab. Both patients were HLA-A11:01 subtype and their tumor harbors KRAS G12V mutation. Consistent with the clinical findings, both patients had a significant expansion of polyfunctional, KRAS G12V-specific CD8 cytotoxic T cells with high levels of INF-γ and TNF-α upon neoantigen stimulation.